Method for predicting severity and prognosis of cardiovascular disease

Patent metadata

Field	Value
Publication number	US-11651859-B2
Application number	US-201816227097-A
Country	US
Kind code	B2
Filing date	Dec 20, 2018
Priority date	Dec 25, 2017
Publication date	May 16, 2023
Grant date	May 16, 2023

Abstract

Disclosed is a method comprising acquiring a value relating to VEGF-A of a subject, wherein the value is a measured value of total VEGF-A in a blood sample, or a value obtained by dividing a measured value of VEGF-A165b in the blood sample by a measured value of total VEGF-A in the blood sample (VEGF-A165b/total VEGF-A), and the value suggests prognosis of myocardial infarction of the subject or severity of coronary artery disease of the subject.

First claim

What is claimed is:

1. A method for detecting VEGF-A and VEGF-A 165 b in a subject with coronary artery disease or following myocardial infarction, said method comprising:
measuring, by immunoassay using an anti-total VEGF-A antibody, the amount of total VEGF-A in a blood sample obtained from the subject, wherein the amount of total VEGF-A in said sample is measured by detecting, via a detection apparatus, a detectable signal produced by the immunoassay;
measuring, by immunoassay using an antibody that specifically binds to anti-VEGF-A 165 b, the amount of VEGF-A 165 b in said sample, wherein the amount of VEGF-A 165 b in said sample is measured by detecting, via a detection apparatus, a detectable signal produced by the immunoassay,
acquiring, by a hardware processor, measurement values for the measured amounts of total VEGF-A and VEGF-A 165 b in said sample;
determining from the acquired measurement values, via the hardware processor, the proportion of total VEGF-A that is VEGF-A 165 b in said sample; and
comparing, via the hardware processor, the determined proportion of total VEGF-A that is VEGF-A 165 b in said sample to a corresponding reference proportion,
wherein when said subject is a subject following myocardial infarction, said method further comprises determining, via the hardware processor, that the prognosis of the myocardial infarction of the subject is poor when the proportion of total VEGF-A that is VEGF-A 165 b in said sample is higher than the corresponding reference proportion and displaying a result from which a diagnosis may be made based on determining that the prognosis of the myocardial infarction of the subject is poor.

2. The method according to claim 1 , wherein said corresponding reference proportion is obtained from a group of subjects having a good prognosis following myocardial infarction.

3. The method according to claim 1 , wherein when said subject is a subject following myocardial infarction, said method further comprises determining that the prognosis of the myocardial infarction of the subject is good when the proportion of total VEGF-A that is VEGF-A 165 b in said sample is lower than a corresponding reference proportion.

4. The method according to claim 1 , wherein the poor prognosis comprises the high risk of occurrence of major adverse cardiac and cerebrovascular events.

5. The method according to claim 4 , wherein the major adverse cardiac and cerebrovascular events comprise one or more events selected from the group consisting of cardiovascular death, recurrence of nonfatal myocardial infarction, reapplication of coronary artery revascularization surgery, and cerebral infarction.

6. The method according to claim 1 , wherein when said subject is a subject with coronary artery disease, said method further comprises determining that the subject has severe coronary artery disease when the proportion of total VEGF-A that is VEGF-A 165 b in said sample is lower than a corresponding reference proportion.

7. The method according to claim 6 , wherein said severe coronary artery disease has a SYNTAX score of more than 22.

8. The method according to claim 1 , wherein when said subject is a subject with coronary artery disease, said method further comprises determining that the subject has non-severe coronary artery disease when the proportion of total VEGF-A that is VEGF-A 165 b in said sample is higher than a corresponding reference proportion.

9. The method according to claim 8 , wherein said corresponding reference proportion is obtained from a group of subjects having severe coronary artery disease.

10. The method according to claim 8 , wherein said non-severe coronary artery disease has a SYNTAX score of 22 or less.

Assignees

• Univ Nagoya Nat Univ Corp
• Sysmex Corp

Inventors

• Kikuchi Ryosuke
• Harada Kazuhiro
• Shibata Yohei
• Ishii Hideki
• Murohara Toyoaki

Classifications

• G16B20/20

  Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection · CPC title

• G01N33/6872

  Intracellular protein regulatory factors and their receptors, e.g. including ion channels · CPC title

• G16H50/30

  for calculating health indices; for individual health risk assessment · CPC title

• A61B5/00 Primary

  Measuring for diagnostic purposes (radiation diagnosis A61B6/00; diagnosis by ultrasonic, sonic or infrasonic waves A61B8/00); Identification of persons · CPC title

• G01N2800/324

  Coronary artery diseases, e.g. angina pectoris, myocardial infarction · CPC title